MWSTP: Established in 2012 from 7 academic institutions in the Midwest with expertise in sarcoma
The 7 academic medical centers (Mayo Clinic, Medical College of Wisconsin, Northwestern University, University of Iowa, University of Minnesota, University of Wisconsin, and Washington University in St. Louis) have established sarcoma programs with medical oncologists with interest and expertise in sarcoma
All these institutions perform clinical trials in sarcoma
Geographically, these centers are in the Midwest (includes Arizona and Florida for Mayo Clinic) and patients in this region have the ability to travel to several of these sites for consultations and participation in clinical trials
Get in touch
Scott Okuno, MD
Scott H. Okuno, M.D., is a medical oncologist with specialty interest is in bone and soft tissue sarcoma. His clinic focus includes:
Managing sarcoma patients in a multi-disciplinary approach
Providing access to clinical trials for patients
Advocate for sarcoma support groups
Managing and overseeing the development and conduct of clinical trials
Assisting oncologists to manage the care of patients locally when appropriate
In addition to his clinical activities, Dr. Okuno is active in research, education, and mentorship to resident, fellows, and junior staff. He published articles in high-impact scientific journals. Dr. Okuno leads the sarcoma medical oncology program at Mayo Clinic and is Chair of Oncology of Mayo Clinic Health System in Eau Claire, Wisconsin.
Read more about Dr. Okuno’s education, certification and awards here.
Brittany Siontis, MD
Read more about Dr. Siontis’s education, certification and awards here.
Eva Galanis, MD
Evanthia Galanis, M.D., has a long-standing interest in developing novel therapeutic approaches for cancer treatment. The focus of her laboratory is to develop and optimize novel virotherapy approaches with special emphasis on paramyxoviruses. A number of different strategies are tested, including use of therapeutic transgenes; trackable markers; combinations with small molecules, cytotoxic agents and radiation therapy; re-targeting of viral strains against tumor-specific antigens; development of novel viral delivery approaches; and exploration of immunomodulatory methods to modify humoral and innate immunity as a means of optimizing virotherapy efficacy.
A significant impetus for Dr. Galanis' research has been the translation of laboratory advances into clinical trials of novel virotherapeutics and small molecules in cancer patients. She has served as the principal investigator in multiple phase I and II virotherapy trials in different solid tumors (ovarian cancer, glioblastoma, renal cell carcinoma, colorectal cancer, melanoma, hepatocellular carcinoma), and she has spearheaded the clinical translation of measles derivatives and their first human testing in patients with ovarian cancer or brain tumors, as well as first human use of live cell carriers for oncolytic virus delivery.
Read more about Dr. Galanis’s education, certification and awards here.
university of iowa
Mohammed Milhem, MD
Read more about Dr. Milhem’s education, certification and awards here.
university of Minnesota
Keith Skubitz, MD
Dr. Skubitz has led the medical oncology arm of the Bone and Soft Tissue Tumor program at the University since 1988. He received an AB in physics and chemistry from Cornell University and an MD from the Johns Hopkins University School of Medicine, and then did internal medicine training at the University of Minnesota. He completed two fellowships, one in Clinical Pharmacology at Johns Hopkins and one in Medical Oncology at the University of Minnesota.
Read more about Dr. Skubitz’s education, certification and awards here.